슬롯 사이트

Interest in Novo Nordisk’s obesity treatment drug, 슬롯 사이트, appears to have cooled within three months of its launch. Factors such as high cost, internal competition with Saxenda, and telemedicine prescription restrictions are believed to be contributing to the decline.

According to pharmaceutical distribution networks and pharmacies, 슬롯 사이트’s prescription volume has been steadily decreasing since its non-reimbursed launch in October 2024, despite initial enthusiasm from the industry. Distribution data confirms this trend. As of February 25, 2024, a leading South Korean distributor reported that pharmacy shipments had fallen to half of December’s volume. Another major distributor indicated that inbound shipments in January had dropped by over 40% compared to the previous month. Several other firms, while withholding exact figures, confirmed a notable decline in pharmacy sales within one to two months. Given that 슬롯 사이트 is supplied through both hospital-direct and pharmacy channels, the rapid downturn has drawn significant industry attention. Some distributors even opted out of stocking 슬롯 사이트 in January and February.

A key point of concern is the distribution of different dosage strengths. The 1.7mg formulation has seen lower shipment and usage levels compared to earlier doses. 슬롯 사이트 follows a titration regimen, starting at 0.25mg and gradually increasing to 0.5mg, 1.0mg, 1.7mg, and a maximum of 2.4mg. Given the four-week dosing increments, most patients would have reached the 1.7mg dosage between mid-January and late January.

While a decline in 2.4mg prescriptions could be linked to concerns over side effects, the reduced uptake of the 1.7mg dose suggests that long-term adherence is weakening. Industry experts speculate that many patients discontinue treatment beyond the initial phase.

A South Korean pharmaceutical distribution official commented, "The supply decline beyond the intermediate 1.0mg dosage indicates that patients may be hesitant to increase their dose or face obstacles preventing them from continuing treatment."

Another major factor is the government’s recent restriction on obesity drug prescriptions via telemedicine. On November 29, the Ministry of Health and Welfare (MOHW) announced that, starting December 2, obesity medications, including 슬롯 사이트, could no longer be prescribed through remote consultations. This policy shift likely dampened demand, making it harder for patients to progress to higher dosages. With pharmacies only allowed to dispense previously prescribed medications until December 15, a drop in 1.7mg prescriptions by mid-January aligns with expectations.

슬롯 사이트’s price competitiveness also remains a challenge. While some clinics in districts like Gangnam, Seoul, have lowered the monthly cost to the high 0 range, it is still at least more expensive than alternatives. Significant regional price variations between Saxenda and 슬롯 사이트 suggest that many patients prioritize cost over convenience.

Meanwhile, industry speculation suggests that Eli Lilly may fast-track the launch of its obesity drug, Zepbound, in response to 슬롯 사이트’s struggles. Reports indicate that Lilly had initially planned for a first-half launch but may accelerate its market entry to capitalize on 슬롯 사이트’s stagnation before broader interest in obesity treatments wanes.

With 슬롯 사이트 struggling to maintain its early momentum, all eyes are now on Novo Nordisk’s next steps to regain market traction.